EUCTR2021-002203-34-Outside-EU/EEA进行中（未招募）1 期
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis - M16-813
AbbVie Deutschland0 个研究点开始时间: 2021年4月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- adults who are = 18 years old and, where locally permissible and approved, adolescent subjects who are at least 12 years old
- •- a diagnosis of atopic dermatitis (AD) with onset of symptoms at least 2 years prior to Baseline and subject meets Hanifin and Rajka criteria
- •- moderate to severe AD at the Baseline Visit
- •- history of inadequate response to previous topical corticosteroid and/or topical calcineurin inhibitor treatments or a medical inability to receive these treatments
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 155
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 153
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- prior exposure to any biologic immunomodulatory agent or Janus kinase (JAK) inhibitor
- •- concurrent treatment with systemic therapy for AD (biologic or non-biologic) or topical and/or phototherapy treatments
研究者
相似试验
进行中（未招募）
1 期
A global study comparing ABBV-066 to placebo in adult subjects with Hidradenitis SuppurativaMedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858Hidradenitis SuppurativaEUCTR2019-000122-21-NLAbbVie Deutschland GmbH & Co. KG220
进行中（未招募）
1 期
A Proof-of-Concept Study of Guselkumab in the Treatment of Subjects with Moderate to Severe Hidradenitis SuppurativaEUCTR2018-001176-38-DKJanssen-Cilag International NV180
进行中（未招募）
1 期
A global study comparing ABBV-066 to placebo in adult subjects with Hidradenitis SuppurativaHidradenitis SuppurativaEUCTR2019-000122-21-FRAbbVie Deutschland GmbH & Co. KG190
进行中（未招募）
1 期
A Proof-of-Concept Study of Guselkumab in the Treatment of Subjects with New-Onset or Relapsing Giant Cell ArteritisGiant Cell ArteritisEUCTR2020-000622-26-PLJanssen-Cilag International N.V.51
进行中（未招募）
1 期
A global study comparing ABBV-066 to placebo in adult subjects with Hidradenitis SuppurativaHidradenitis SuppurativaEUCTR2019-000122-21-ESAbbVie Deutschland GmbH & Co. KG190